These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 23628403)
1. In vitro-in vivo evaluation of nanosuspension release from subcutaneously implantable osmotic pumps. Hill A; Geissler S; Meyring M; Hecht S; Weigandt M; Mäder K Int J Pharm; 2013 Jul; 451(1-2):57-66. PubMed ID: 23628403 [TBL] [Abstract][Full Text] [Related]
2. How do in-vitro release profiles of nanosuspensions from Alzet® pumps correspond to the in-vivo situation? A case study on radiolabeled fenofibrate. Hill A; Breyer S; Geissler S; Mier W; Haberkorn U; Weigandt M; Mäder K J Control Release; 2013 May; 168(1):77-87. PubMed ID: 23499716 [TBL] [Abstract][Full Text] [Related]
3. Controlled delivery of nanosuspensions from osmotic pumps: zero order and non-zero order kinetics. Hill A; Geissler S; Weigandt M; Mäder K J Control Release; 2012 Mar; 158(3):403-12. PubMed ID: 22198270 [TBL] [Abstract][Full Text] [Related]
4. Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization: an in vitro and in vivo evaluation. Hong C; Dang Y; Lin G; Yao Y; Li G; Ji G; Shen H; Xie Y Int J Pharm; 2014 Dec; 477(1-2):251-60. PubMed ID: 25445518 [TBL] [Abstract][Full Text] [Related]
5. Development of novel polymer-stabilized diosmin nanosuspensions: in vitro appraisal and ex vivo permeation. Freag MS; Elnaggar YS; Abdallah OY Int J Pharm; 2013 Sep; 454(1):462-71. PubMed ID: 23830765 [TBL] [Abstract][Full Text] [Related]
6. Nanosuspensions of poorly soluble drugs: preparation and development by wet milling. Liu P; Rong X; Laru J; van Veen B; Kiesvaara J; Hirvonen J; Laaksonen T; Peltonen L Int J Pharm; 2011 Jun; 411(1-2):215-22. PubMed ID: 21458552 [TBL] [Abstract][Full Text] [Related]
7. Development of ALZET® osmotic pump compatible solvent compositions to solubilize poorly soluble compounds for preclinical studies. Gullapalli R; Wong A; Brigham E; Kwong G; Wadsworth A; Willits C; Quinn K; Goldbach E; Samant B Drug Deliv; 2012; 19(5):239-46. PubMed ID: 22656673 [TBL] [Abstract][Full Text] [Related]
8. Controlled delivery of carvedilol nanosuspension from osmotic pump capsule: in vitro and in vivo evaluation. Liu D; Yu S; Zhu Z; Lyu C; Bai C; Ge H; Yang X; Pan W Int J Pharm; 2014 Nov; 475(1-2):496-503. PubMed ID: 25219321 [TBL] [Abstract][Full Text] [Related]
9. Nanosuspensions of poorly water-soluble drugs prepared by bottom-up technologies. Du J; Li X; Zhao H; Zhou Y; Wang L; Tian S; Wang Y Int J Pharm; 2015 Nov; 495(2):738-49. PubMed ID: 26383838 [TBL] [Abstract][Full Text] [Related]
10. Development and comparison of intramuscularly long-acting paliperidone palmitate nanosuspensions with different particle size. Leng D; Chen H; Li G; Guo M; Zhu Z; Xu L; Wang Y Int J Pharm; 2014 Sep; 472(1-2):380-5. PubMed ID: 24882037 [TBL] [Abstract][Full Text] [Related]
11. Stability of nanosuspensions in drug delivery. Wang Y; Zheng Y; Zhang L; Wang Q; Zhang D J Control Release; 2013 Dec; 172(3):1126-41. PubMed ID: 23954372 [TBL] [Abstract][Full Text] [Related]
12. Poloxamer 407 microspheres for orotransmucosal drug delivery. Part I: formulation, manufacturing and characterization. Albertini B; Passerini N; Di Sabatino M; Monti D; Burgalassi S; Chetoni P; Rodriguez L Int J Pharm; 2010 Oct; 399(1-2):71-9. PubMed ID: 20696227 [TBL] [Abstract][Full Text] [Related]
13. Preparation and characterization of freeze-dried 2-methoxyestradiol nanoparticle powders. Du B; Li XT; Zhao Y; A YM; Zhang ZZ Pharmazie; 2010 Jul; 65(7):471-6. PubMed ID: 20662313 [TBL] [Abstract][Full Text] [Related]
14. Diclofenac nanosuspensions: influence of preparation procedure and crystal form on drug dissolution behaviour. Lai F; Sinico C; Ennas G; Marongiu F; Marongiu G; Fadda AM Int J Pharm; 2009 May; 373(1-2):124-32. PubMed ID: 19429297 [TBL] [Abstract][Full Text] [Related]
15. Studies on pharmacokinetics and tissue distribution of bifendate nanosuspensions for intravenous delivery. Liu Y; Zhang D; Duan C; Jia L; Xie P; Zheng D; Wang F; Liu G; Hao L; Zhang X; Zhang Q J Microencapsul; 2012; 29(2):194-203. PubMed ID: 22172025 [TBL] [Abstract][Full Text] [Related]
16. Development of PIK-75 nanosuspension formulation with enhanced delivery efficiency and cytotoxicity for targeted anti-cancer therapy. Talekar M; Ganta S; Amiji M; Jamieson S; Kendall J; Denny WA; Garg S Int J Pharm; 2013 Jun; 450(1-2):278-89. PubMed ID: 23632263 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of pluronic nanosuspensions loading a novel insoluble anticancer drug both in vitro and in vivo. Tang XJ; Fu YH; Meng QH; Li LM; Ying XY; Han M; He QJ; Yang B; Zeng S; Hu YZ; Sheng XX; Gao JQ Int J Pharm; 2013 Nov; 456(1):243-50. PubMed ID: 23928148 [TBL] [Abstract][Full Text] [Related]
18. Preparation of a chemically stable quercetin formulation using nanosuspension technology. Gao L; Liu G; Wang X; Liu F; Xu Y; Ma J Int J Pharm; 2011 Feb; 404(1-2):231-7. PubMed ID: 21093559 [TBL] [Abstract][Full Text] [Related]
19. Preparation of ritonavir nanosuspensions by microfluidization using polymeric stabilizers: I. A Design of Experiment approach. Karakucuk A; Celebi N; Teksin ZS Eur J Pharm Sci; 2016 Dec; 95():111-121. PubMed ID: 27181836 [TBL] [Abstract][Full Text] [Related]
20. Formulation and comparative evaluation of HPMC and water soluble chitosan-based sparfloxacin nanosuspension for ophthalmic delivery. Ambhore NP; Dandagi PM; Gadad AP Drug Deliv Transl Res; 2016 Feb; 6(1):48-56. PubMed ID: 26545605 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]